Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
Renata FerrarottoDiana BellMaria L RubinKatherine A HutchesonJason M JohnsonRyan P GoepfertJack PhanYasir Y ElaminDanice K TormanCarla L WarnekeAmy C HesselAdam S GardenJeffrey N MyersFaye M JohnsonJ Jack LeeAndrew G SikoraMaura L GillisonBonnie S GlissonNeil D GrossPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Durvalumab + tremelimumab did not increase CD8+TIL density more than durvalumab alone did. The observed safety and activity support further investigation of neoadjuvant checkpoint inhibitor for OPC.